본문 바로가기
bar_progress

Text Size

Close

3592 Cases of Vaccine Adverse Reactions Over Three Days... Death Reports Increase by 14

3592 Cases of Vaccine Adverse Reactions Over Three Days... Death Reports Increase by 14 Citizens are receiving COVID-19 vaccinations at Yonsei ENT Clinic in Dongjak-gu, Seoul. [Image source=Yonhap News]


[Asia Economy Reporter Seongpil Cho] The number of reported adverse reactions following COVID-19 vaccination has increased by nearly 3,600 cases over the past three days.


According to the COVID-19 Vaccination Response Promotion Team (Promotion Team) on the 5th, a total of 3,592 new cases suspected of adverse reactions after vaccination were reported to health authorities from the 2nd to the 4th. The daily numbers were 1,174 on the 2nd, 1,125 on the 3rd, and 1,293 on the 4th, each exceeding 1,000 cases per day.


Since the start of vaccinations in Korea on February 26, the cumulative number of suspected adverse reaction reports has reached 33,442. This accounts for approximately 0.34% of the total 9,732,863 first and second dose vaccinations administered nationwide as of midnight on that day.


Breaking down by vaccine type, there have been 25,074 reports related to the AstraZeneca (AZ) vaccine and 8,368 reports related to the Pfizer vaccine. The reporting rate of adverse reactions relative to the cumulative number of vaccinations is about 0.46% for the AstraZeneca vaccine and 0.19% for the Pfizer vaccine.


The number of death reports increased by 14. Among them, 6 were recipients of the AstraZeneca (AZ) vaccine, and 8 had received the Pfizer vaccine. This brings the cumulative number of death reports after vaccination to 206 (134 for the Pfizer vaccine and 72 for the AstraZeneca vaccine). Including cases where symptoms were initially reported and later worsened resulting in death, the total number of deaths is 278.


The quarantine authorities announce statistics on adverse reaction reports three times a week, on Mondays, Wednesdays, and Saturdays.


© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Special Coverage


Join us on social!

Top